Publication | Closed Access

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study

Chemotherapy Versus PlaceboEsophageal CancerGastrointestinal OncologyMedicineClinical TrialsPathologyFirst-line TreatmentCancer TreatmentOncologyRadiation OncologyHealth Sciences